This week’s Gene and Cell Therapy update highlights regulatory progress, late-stage clinical development, new approvals, strategic partnerships, and advancing gene and cell therapy programs across multiple indications.
In Today’s Newsletter
Dive deeper
🧬 RGX-202 Duchenne BLA path [1] [US • 24 Jun 2026]
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-completes-dosing-confirmatory-study-rgx-202-marking
Context: RGX-202 (REGENXBIO; Duchenne gene therapy) is in the AFFINITY DUCHENNE pivotal and confirmatory program.
Key point: REGENXBIO completed confirmatory-study dosing and plans to initiate a BLA in Q3 2026 under accelerated approval.
Implication: May influence prescriber choice and payer reviews pending full data.
👁️ Sura-vec enters NAAVIGATE diabetic retinopathy trial [2] [US • 29 Jun 2026]
https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-first-patient-dosed-phase-iibiii-naavigate
Context: Sura-vec (REGENXBIO/AbbVie; ABBV-RGX-314) is being tested by suprachoroidal delivery in NPDR without CI-DME.
Key point: The first patient was dosed in Phase IIb/III NAAVIGATE, triggering a $100 million AbbVie milestone.
Implication: May influence prescriber choice and payer reviews pending full data.
🧠 NGN-401 Rett syndrome long-term data [3] [US • 29 Jun 2026]
https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-positive-long-term-clinical-data-phase-12
Context: NGN-401 (Neurogene; Rett syndrome gene therapy) was evaluated in a Phase 1/2 trial with 12–30 months of follow-up.
Key point: Neurogene reported developmental milestone gains across 10 participants and generally well-tolerated safety at the 1E15 vg dose.
Implication: May influence prescriber choice and payer reviews pending full data.
❄️ Cryoport supports Verismo KIR-CAR T programs [4] [US/EU • 25 Jun 2026]
https://www.prnewswire.com/news-releases/cryoports-integricell-cryopreservation-services-selected-by-verismo-therapeutics-to-support-clinical-kir-car-t-cell-therapy-programs-302810192.html
Context: IntegriCell (Cryoport) provides cryopreservation services across sites in Houston, Texas, and Liège, Belgium.
Key point: Verismo selected IntegriCell to support SynKIR-110 and SynKIR-310, both in Phase 1 clinical testing.
Implication: Signals pipeline investment and modality expansion.
🧫 CARsgen satri-cel solid tumor CAR-T approval [5] [China • 30 Jun 2026]
https://www.fiercebiotech.com/research/china-approved-worlds-first-solid-tumor-car-t-therapy-when-will-us-follow
Context: Satri-cel (CARsgen Therapeutics; Claudin18.2-targeted CAR-T) is for advanced gastric or gastroesophageal junction adenocarcinoma.
Key point: China’s NMPA approved satri-cel on 22 Jun 2026 for HER2-negative, Claudin18.2-positive disease.
Implication: Introduces competition that may affect pricing and formulary access.
🩸 Orca Bio TREGZI FDA approval [6] [US • 30 Jun 2026]
https://www.businesswire.com/news/home/20260630929266/en/Orca-Bios-TREGZI-Receives-U.S.-FDA-Approval-as-First-and-Only-Precision-Engineered-Cell-Therapy-for-Allogeneic-Transplant-in-Adults-with-Hematological-Malignancies
Context: TREGZI (Orca Bio; Orca-T) is a precision-engineered cell therapy for matched-donor alloHSCT in adults with hematological malignancies.
Key point: FDA approval was based on the Phase 3 Precision-T study, which improved chronic GVHD-free survival versus conventional alloHSCT.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Gene therapy programs are moving deeper into registrational development, with RGX-202 and NGN-401 highlighting rare-disease momentum.
- Retinal gene therapy remains active, with REGENXBIO and AbbVie advancing sura-vec in diabetic retinopathy.
- Cell therapy infrastructure is becoming more industrialized, as Cryoport supports Verismo’s KIR-CAR T manufacturing workflow.
- China’s satri-cel approval marks a notable solid tumor CAR-T milestone while US timelines remain uncertain.
- Orca Bio’s TREGZI approval brings engineered-cell precision into allogeneic transplant practice.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Rare Disease archive on our research hub page
FAQ
What is RGX-202 and what did REGENXBIO report?
RGX-202 is REGENXBIO’s investigational Duchenne muscular dystrophy gene therapy. The company completed dosing in the confirmatory study and plans to initiate a BLA in Q3 2026. [1]
What is sura-vec in the NAAVIGATE trial?
Sura-vec, also known as ABBV-RGX-314, is a one-time investigational gene therapy from REGENXBIO and AbbVie for diabetic retinopathy. NAAVIGATE is evaluating suprachoroidal delivery in NPDR without CI-DME. [2]
What did Neurogene report for NGN-401 in Rett syndrome?
Neurogene reported developmental milestone gains in its Phase 1/2 NGN-401 study, with 12–30 months of follow-up. The company also said Embolden registrational dosing is complete. [3]
Which Verismo programs will Cryoport’s IntegriCell support?
IntegriCell will support Verismo’s SynKIR-110 program in mesothelin-expressing solid tumors and SynKIR-310 in relapsed or refractory B-cell non-Hodgkin lymphomas. [4]
Why is CARsgen’s satri-cel approval notable?
Fierce Biotech described satri-cel as the world’s first approved solid tumor CAR-T therapy. China’s NMPA approved it for HER2-negative, Claudin18.2-positive gastric or gastroesophageal junction adenocarcinoma. [5]
What is TREGZI from Orca Bio?
TREGZI, clinically known as Orca-T, is a precision-engineered cell therapy approved by the US FDA for adults with hematological malignancies undergoing matched-donor alloHSCT. [6]
Entities / Keywords
REGENXBIO, RGNX, RGX-202, AFFINITY DUCHENNE, Duchenne muscular dystrophy, BLA, accelerated approval
Sura-vec, surabgene lomparvovec, ABBV-RGX-314, AbbVie, NAAVIGATE, ALTITUDE, ATMOSPHERE, ASCENT, diabetic retinopathy, NPDR, CI-DME, wet AMD
Neurogene, NGN-401, Rett syndrome, Embolden, CGI-I, developmental milestones, AAV gene therapy
Cryoport, IntegriCell, Verismo Therapeutics, SynKIR-110, SynKIR-310, KIR-CAR T, STAR-101, CELESTIAL-301
CARsgen Therapeutics, satri-cel, satricabtagene autoleucel, Claudin18.2, HER2-negative, gastric cancer, GEJ adenocarcinoma, NMPA
Orca Bio, TREGZI, Orca-T, regulatory T cells, Tregs, HSPCs, alloHSCT, GVHD, cGFS, Precision-T
References
- https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-completes-dosing-confirmatory-study-rgx-202-marking
- https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-first-patient-dosed-phase-iibiii-naavigate
- https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-positive-long-term-clinical-data-phase-12
- https://www.prnewswire.com/news-releases/cryoports-integricell-cryopreservation-services-selected-by-verismo-therapeutics-to-support-clinical-kir-car-t-cell-therapy-programs-302810192.html
- https://www.fiercebiotech.com/research/china-approved-worlds-first-solid-tumor-car-t-therapy-when-will-us-follow
- https://www.businesswire.com/news/home/20260630929266/en/Orca-Bios-TREGZI-Receives-U.S.-FDA-Approval-as-First-and-Only-Precision-Engineered-Cell-Therapy-for-Allogeneic-Transplant-in-Adults-with-Hematological-Malignancies